Immatics Biotechnologies GmbH, of Tubingen, Germany, and Biontech AG, of Mainz, Germany, said they are moving into the clinic with a fully personalized therapeutic cancer vaccine approach known as Gapvac (Glioma Actively Personlized VAccine Consortium), with approval in Germany for the start of a phase I/II study to test drugs designed and manufactured for each patient individually according to specific characteristics of their tumors and immune systems.